[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (9,126)

Search Parameters:
Keywords = COX-2

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
9 pages, 1960 KiB  
Article
Can Cryptogonimids of the Same Genus Influence Each Other’s Level of Genetic Variation?
by Ekaterina S. Tokarskaya, Yulia V. Tatonova, Haneef Ahmed Amissah, Polina G. Shumenko and Mikhail Yu. Shchelkanov
Biology 2025, 14(1), 6; https://doi.org/10.3390/biology14010006 (registering DOI) - 24 Dec 2024
Abstract
Trematodes of the genus Exorchis are parasites that are common in East and Southeast Asia. These parasites are known to infect fish, thus impacting aquaculture significantly. An introspection into the dynamics of infection of these parasites has revealed possible co-infection in shared hosts. [...] Read more.
Trematodes of the genus Exorchis are parasites that are common in East and Southeast Asia. These parasites are known to infect fish, thus impacting aquaculture significantly. An introspection into the dynamics of infection of these parasites has revealed possible co-infection in shared hosts. But data on the dynamics of their shared host on their population structure and genetic variability is lacking. In this study, we investigate the intraspecific structure of the Exorchis species, Exorchis oviformis, and E. convictus, both of which coexist in the same definitive host. By using partial gene sequences of the mitochondrial cox1 gene (715 bp), including 30 newly obtained sequences from the southern part of the Russian Far East, we found a low level of genetic variation in both species, consistent with previous findings of other trematodes from the same region. We hypothesize that the observed low variability could be attributable to the process of host infection and transmission and abiotic factors influencing a recent decline in host variability and abundance. This is driving a strong selection pressure due to the limited number of parasites reaching the definitive host. This, among other factors, could possibly impact the long-term survival and adaptability of Exorchis and other trematodes at large in the region. However, we also believe that there may be a chance that these closely related species could exert an influence on each other’s genetic diversity, potentially limiting the variation within each species. To uncover the dynamics driving these observations, we propose the approach of expanding sampling, broader genetic marker analyses, and investigations of varied host populations that could elucidate the complexities of the Exorchis species genetic variability and evolutionary dynamics. Full article
(This article belongs to the Section Genetics and Genomics)
Show Figures

Figure 1

Figure 1
<p>Variable sites of nucleotide sequences of the <span class="html-italic">cox1</span> gene for <span class="html-italic">Exorchis</span> spp. <span class="html-italic">Hap</span>—haplotype; <span class="html-italic">n</span>—number of sequences in the haplotypes. The numbers above the nucleotide sequences show the numbers of the variable sites (should be read vertically). Squares, triangles, and stars represent parasites from catfish 1 from the Elduga River, catfish 2 from the Elduga River, and catfish from the Razdolnaya River, respectively.</p>
Full article ">Figure 2
<p>Mismatch distribution graphs for the partial sequence of the <span class="html-italic">cox1</span> mtDNA gene of <span class="html-italic">Exorchis oviformis</span> (<b>A</b>) and <span class="html-italic">Exorchis convictus</span> (<b>B</b>). <span class="html-italic">Exp</span>, expected distribution, <span class="html-italic">Obs</span>, observed distribution.</p>
Full article ">Figure 3
<p>Minimum spanning tree (MST) based on the <span class="html-italic">cox1</span> mtDNA gene sequences for <span class="html-italic">Exorchis</span> spp. <span class="html-italic">Hap</span>—haplotype; <span class="html-italic">n</span>—number of sequences in the haplotypes. Square, triangle, and star are parasites from catfish 1 from the Elduga River, catfish 2 from the Elduga River, and catfish from the Razdolnaya River, respectively.</p>
Full article ">
17 pages, 796 KiB  
Article
Association Between Adolescent Violence Exposure and the Risk of Suicide: A 15-Year Study in Taiwan
by Chieh Sung, Chi-Hsiang Chung, Chien-An Sun, Chang-Huei Tsao, Daphne Yih Ng, Tsu-Hsuan Weng, Li-Yun Fann, Fu-Huang Lin and Wu-Chien Chien
Children 2025, 12(1), 10; https://doi.org/10.3390/children12010010 - 24 Dec 2024
Abstract
Background/Objectives: According to the 2023 Ministry of Health and Welfare statistics, the suicide rate among adolescents aged 15 to 24 has steadily increased since 2018, from 3.7 to 5.5 per 100,000 populations, reaching a recent high. Although previous studies have pointed out that [...] Read more.
Background/Objectives: According to the 2023 Ministry of Health and Welfare statistics, the suicide rate among adolescents aged 15 to 24 has steadily increased since 2018, from 3.7 to 5.5 per 100,000 populations, reaching a recent high. Although previous studies have pointed out that the future risk of suicide of those who had suffered from abuse was higher than that of the general population, researchers seldom focused on adolescent groups. Therefore, the aim of this study was to explore the risk of suicide after youth violence and the impact of subsequent comorbid mental illness and suicide risk. Methods: This retrospective matched cohort study analyzed data from the NHIRD, covering the period from 2000 to 2015. A total of 976 cases aged 10–18 who had experienced violence were included in this study. Controlled grouping was conducted by 1:10 matching based on gender, age, and the time of medical treatment, and a control group who had not experienced violence was selected for comparison. We used the Cox proportional hazards model to analyze the risk of suicide among adolescents after exposure to violence. Results: The suicide rate among adolescents who have experienced violence was significantly higher than that of the control group after 15 years of follow-up (1.0% vs. 0.5%). The prevalence of mental illness or disorders in adolescents exposed to violence was significantly higher than in the control group (45.2% vs. 40.1%). Among adolescents who had experienced violence, the methods of suicide included poisoning (solid and liquid) (53.6% vs. 43.2%), hanging (1.2% vs. 0.6%), firearms (2.4% vs. 0%), and cutting instruments (27.4% vs. 22.8%), all of which were significantly higher than in the control group. After adjusting for gender, age, residential area, and mental health comorbidities, the risk of suicide in those who had experienced violence was 1.475 times that of the control group (95% CI = 1.125–1.933; p = 0.005). Conclusions: In this study, female, younger age, and comorbid mental disorders were identified as risk factors for suicide among the adolescent victims of violence. Exposure to youth violence was associated with an increased prevalence of emotional disorders, including depression and social isolation, which subsequently elevated the suicide risk. These findings underscore the urgent need for governmental attention to the mental health of adolescent victims of violence. Implementing targeted psychological support and intervention programs could play a crucial role in mitigating the risk of suicide among this vulnerable population. Full article
(This article belongs to the Section Global Pediatric Health)
13 pages, 2121 KiB  
Article
The Electroanatomic Volume of the Left Atrium as a Determinant of Recurrences in Patients with Atrial Fibrillation After Pulmonary Vein Isolation: A Prospective Study
by Amaia Martínez León, David Testa Alonso, María Salgado, Ruth Álvarez Velasco, Minel Soroa, Daniel Gracia Iglesias and David Calvo
Biomedicines 2025, 13(1), 7; https://doi.org/10.3390/biomedicines13010007 - 24 Dec 2024
Abstract
Background/Objectives: Catheter ablation for atrial fibrillation (AF) is a well-established therapeutic approach for maintaining sinus rhythm, though its efficacy remains suboptimal in certain patients. The left atrium (LA) volume, commonly assessed through transthoracic echocardiography (TTE), is a recognized predictor of AF recurrence [...] Read more.
Background/Objectives: Catheter ablation for atrial fibrillation (AF) is a well-established therapeutic approach for maintaining sinus rhythm, though its efficacy remains suboptimal in certain patients. The left atrium (LA) volume, commonly assessed through transthoracic echocardiography (TTE), is a recognized predictor of AF recurrence after pulmonary vein isolation (PVI). However, the complex three-dimensional structure of the LA makes precise measurement challenging with traditional TTE techniques. Electroanatomic mapping (EAM) offers a more accurate evaluation of LA geometry and volume, which may enhance the prediction of ablation outcomes. Methods: This prospective study included 197 patients with AF who were referred for PVI to our center (Hospital Universitario Central de Asturias, Spain) between 2016 and 2020. All participants underwent pre-ablation TTE and EAM to assess the electric active volume (EAV) of the LA. Clinical follow-up included regular Holter monitoring and electrocardiograms to detect AF recurrences. Results: The mean age was 56.3 ± 9.67 years, and 34% had persistent AF. The mean LA volumes measured by TTE and the EAV by EAM were 62.86 ± 15.58 mL and 126.75 ± 43.35 mL, respectively, with a moderate positive correlation (r = 0.49, p < 0.001). AF recurrences were observed in 51.27% of patients over a 36 ± 15-month follow-up period. Cox regression analyses (univariate and multivariate), Kaplan–Meier curves and log-rank tests were used to illustrate freedom from atrial arrhythmia during follow-up. Both EAV by EAM and TTE volumes were significant predictors of AF recurrence in the univariate analysis (HR 1.002 [1.001–1.003], p = 0.033 and HR 1.001 [1.006–1.012], p < 0.01, respectively). Among clinical variables, persistent AF was significantly associated with a higher risk of recurrence (HR 1.17 [1.096–1.268], p = 0.02). Conclusions: EAV of the LA assessment by EAM demonstrates a significant correlation with TTE measurements and is a predictor of AF post-ablation recurrence. In patients selected for catheter ablation, EAV by EAM provides additional insights that could contribute to therapeutic decision-making and risk stratification of AF recurrences. Full article
Show Figures

Figure 1

Figure 1
<p>Study design flowchart. EAV, electrically active volume; ECG, electrocardiogram; PV, Pulmonary veins; PVI, Pulmonary vein isolation.</p>
Full article ">Figure 2
<p>Sample case of left atrial electrically active volume (EAV) quantification using electroanatomic mapping. (<b>A</b>) Anterior view. (<b>B</b>) Posterior view. Upper panels display EAV quantified between the plane of the mitral valve and the external limit of the pulmonary veins (PV) set by voltage mapping at 0.2 mV. Lower panels display quantification of excluded atrial volumes by the circumferential pulmonary vein isolation (CPVI) lines.</p>
Full article ">Figure 3
<p>Comparison between Left Atrial volume measured with transthoracic echocardiography and the electrically active volume by EAM. The regression line is plotted in red. EAM: electroanatomic mapping.</p>
Full article ">Figure 4
<p>Cumulative risk of Atrial Fibrillation recurrence during follow-up depending on Left Atrial (LA) volume. (<b>A</b>) LA volume measured by transthoracic echocardiography; red indicates LA volume &lt;60 mL and blue indicates LA volume &gt;60 mL. (<b>B</b>) Electrically active volume (EAV) measured by electroanatomic mapping; red indicates EAV &lt;145 mL, and blue indicates EAV &gt;145 mL.</p>
Full article ">Figure 5
<p>Comparative ROC curves of measurements by transthoracic echocardiography (TTE) and electrically active volume measured by electroanatomic mapping (EAV by EAM), demonstrating similar predictive capabilities for both diagnostic tests.</p>
Full article ">
9 pages, 391 KiB  
Article
Point-Based Prediction Model for Bladder Cancer Risk in Diabetes: A Random Survival Forest-Guided Approach
by Sarah Tsz Yui Yau, Chi Tim Hung, Eman Yee Man Leung, Ka Chun Chong, Albert Lee and Eng Kiong Yeoh
J. Clin. Med. 2025, 14(1), 4; https://doi.org/10.3390/jcm14010004 - 24 Dec 2024
Abstract
Background: Previous epidemiological studies have shown that diabetes is associated with an increased risk of several cancers, including bladder cancer. However, prediction models for bladder cancer among diabetes patients remain scarce. This study aims to develop a scoring system for bladder cancer risk [...] Read more.
Background: Previous epidemiological studies have shown that diabetes is associated with an increased risk of several cancers, including bladder cancer. However, prediction models for bladder cancer among diabetes patients remain scarce. This study aims to develop a scoring system for bladder cancer risk prediction among diabetes patients who receive routine care in general outpatient clinics using a machine learning-guided approach. Methods: A territory-wide retrospective cohort study was conducted using electronic health records of Hong Kong. Patients who received diabetes care in public general outpatient clinics between 2010 and 2019 without a history of malignancy were identified and followed up until December 2019. To develop a scoring system for bladder cancer risk prediction, random survival forest was employed to guide variable selection, and Cox regression was subsequently applied for weight assignment. Results: Of the 382,770 patients identified, 644 patients developed bladder cancer during follow-up (median: 6.2 years). The incidence rate was 0.29 per 1000 person-years. In the final time-to-event scoring system, age, serum creatinine, sex, and smoking were included as predictors. Serum creatinine ≥94 µmol/L appeared to be associated with an increased risk of developing bladder cancer. The 2-year and 5-year AUCs on test set were 0.88 (95%CI: 0.84–0.92) and 0.86 (95%CI: 0.80–0.92) respectively. Conclusions: Renal dysfunction could be a potential predictor of bladder cancer among diabetes patients. The proposed scoring system could be potentially useful for providing individualized risk prediction among diabetes patients. Full article
(This article belongs to the Section Epidemiology & Public Health)
Show Figures

Figure 1

Figure 1
<p>Kaplan-Meier bladder cancer-free survival curves among diabetes patients on test set by risk score.</p>
Full article ">
8 pages, 1088 KiB  
Article
No Significant Association Between Herpes Zoster and Breast Cancer: A German Outpatient Study with over 120,000 Participants
by Vedanth D. Krishnan, Niklas Gremke, André Hajek, Karel Kostev and Matthias Kalder
Clin. Pract. 2024, 14(6), 2770-2777; https://doi.org/10.3390/clinpract14060218 - 23 Dec 2024
Abstract
Purpose: The purpose of this study was to investigate a possible association between Herpes Zoster (HZ) and the subsequent diagnosis of breast cancer (BC). Methods: Utilizing the Disease Analyzer database, anonymized medical records from German office-based practices were accessed. Longitudinal data of female [...] Read more.
Purpose: The purpose of this study was to investigate a possible association between Herpes Zoster (HZ) and the subsequent diagnosis of breast cancer (BC). Methods: Utilizing the Disease Analyzer database, anonymized medical records from German office-based practices were accessed. Longitudinal data of female patients aged 18 years and above diagnosed with HZ between 2005 and 2021 were included. Individuals without HZ diagnoses were matched to HZ patients using a nearest neighbor propensity score matching (1:1) based on age, sex, index year, average yearly consultation frequency during the follow-up, and predefined co-diagnoses. The incidence of BC in the cohort with and without HZ was evaluated using Kaplan–Meier curves and compared using the log-rank test. Finally, a univariable Cox regression analysis was conducted to assess the association between HZ and BC. Results: This study included 64,255 women with HZ and an equal number without HZ, with comparable characteristics in terms of age, visit frequency, and comorbidities. Analysis revealed no significant association between HZ and subsequent BC incidence, with similar rates observed in both HZ and non-HZ cohorts across different age groups. Conclusions: In this retrospective cohort study consisting of well-matched patients, the results indicate no significant association between an HZ infection and the development of BC over a 10-year follow-up period. This is the largest study of its kind to date. Full article
Show Figures

Figure 1

Figure 1
<p>Selection of study patients.</p>
Full article ">Figure 2
<p>Cumulative incidence of breast cancer in female patients with and without herpes zoster.</p>
Full article ">
12 pages, 692 KiB  
Article
Incidence of Total Knee Arthroplasty in Older Females with Knee Osteoarthritis and Osteoporosis Treated with Denosumab Compared with Those Treated Using Bisphosphonates: A Population-Based Cohort Study
by Tzai-Chiu Yu, Wen-Tien Wu, Ru-Ping Lee, Ing-Ho Chen, Jen-Hung Wang, Shu-Hui Wen and Kuang-Ting Yeh
Life 2024, 14(12), 1704; https://doi.org/10.3390/life14121704 - 23 Dec 2024
Abstract
This study aimed to evaluate the incidence of total knee arthroplasty (TKA), a marker of severe knee osteoarthritis (OA), among older females with concurrent knee OA and osteoporosis (OP) who were treated with denosumab or bisphosphonates. By analyzing a large population-based cohort, we [...] Read more.
This study aimed to evaluate the incidence of total knee arthroplasty (TKA), a marker of severe knee osteoarthritis (OA), among older females with concurrent knee OA and osteoporosis (OP) who were treated with denosumab or bisphosphonates. By analyzing a large population-based cohort, we sought to clarify how these treatments influence the progression of knee OA to the point of requiring surgical intervention. We used data from the Taiwan National Health Insurance Research Database, including data from females aged ≥ 50 years diagnosed with knee OA and OP who initiated treatment between 2012 and 2019. Propensity score matching (1:1) resulted in the selection of 13,774 patients (6897 per group). The TKA incidence was analyzed using Cox proportional hazards models. Patients treated with denosumab had a lower TKA incidence than those treated with bisphosphonates (6.9 vs. 8.5 per 1000 person-years). The adjusted hazard ratio (aHR) for TKA in the denosumab group was 0.77 (95% CI: 0.62–0.97; p = 0.024), with the most pronounced effect observed in patients aged ≥ 80 years (aHR = 0.39, 95% CI: 0.20–0.77; p = 0.007). These findings suggest that denosumab reduces TKA risk more effectively than bisphosphonates and may serve as a superior treatment option for mitigating severe knee OA progression, especially in older adults. Full article
(This article belongs to the Special Issue Current Views on Knee Osteoarthritis: 2nd Edition)
Show Figures

Figure 1

Figure 1
<p>The flowchart of this cohort study.</p>
Full article ">Figure 2
<p>The cumulative incidence of total knee arthroplasty of female patients with knee osteoarthritis and osteoporosis who have received bisphosphonates or denosumab treatment (<span class="html-italic">n</span> = 13,774). * <span class="html-italic">p</span>-value &lt; 0.05 was considered statistically significant after test.</p>
Full article ">
12 pages, 768 KiB  
Article
Impact of the Spinal Instability Neoplastic Score on Postoperative Prognosis in Patients with Metastatic Cancer of the Cervical Spine
by Dong-Ho Kang, Kyunghun Jung, Jin-Sung Park, Minwook Kang, Chong-Suh Lee and Se-Jun Park
J. Clin. Med. 2024, 13(24), 7860; https://doi.org/10.3390/jcm13247860 - 23 Dec 2024
Abstract
Background: Although the Spinal Instability Neoplastic Score (SINS) is widely utilized to evaluate spinal instability, its prognostic value for survival in patients with cervical spinal metastases remains unclear. This study investigated the association between the SINS and survival outcomes in patients with metastatic [...] Read more.
Background: Although the Spinal Instability Neoplastic Score (SINS) is widely utilized to evaluate spinal instability, its prognostic value for survival in patients with cervical spinal metastases remains unclear. This study investigated the association between the SINS and survival outcomes in patients with metastatic cervical spine cancer. Methods: This retrospective cohort study included 106 patients who underwent surgery for metastatic cervical spine cancer at a single institution between 1995 and 2023. Patients were divided into two groups: high SINS (≥13) and low-to-moderate SINS (0–12). Overall survival (OS) was the primary outcome and was analyzed using Kaplan–Meier estimates and Cox regression. Secondary outcomes included changes in Eastern Cooperative Oncology Group Performance Status (ECOG-PS), operation time, estimated blood loss, and postoperative complications. Results: The median OS was significantly shorter in the high SINS group compared to the low-to-moderate SINS group (5.3 months versus 8.6 months; p = 0.023). A high SINS was independently associated with increased mortality risk (hazard ratio [HR], 1.959; 95% CI, 1.221–3.143; p = 0.005). Lung cancer (HR, 4.004; 95% CI, 1.878–8.535; p < 0.001) and rectal cancer (HR, 3.293; 95% CI, 1.126–9.632; p = 0.029) were predictive of worse survival, whereas postoperative chemotherapy (HR, 0.591; 95% CI, 0.381–0.917; p = 0.019) and radiotherapy (HR, 0.531; 95% CI, 0.340–0.827; p = 0.005) were associated with improved survival. Changes in the ECOG-PS and postoperative complication rates were not significantly different between the groups. Conclusions: A high SINS was associated with significantly shorter survival in patients with metastatic cervical spine cancer, reflecting both mechanical instability and tumor aggressiveness. Full article
(This article belongs to the Special Issue Recent Advances in Spine Tumor Diagnosis and Treatment)
Show Figures

Figure 1

Figure 1
<p>Kaplan–Meier survival curve showing the overall survival of 106 patients with metastatic cervical spine cancer.</p>
Full article ">Figure 2
<p>Kaplan–Meier survival curve comparing overall survival between the low-to-moderate SINS group (median survival: 8.6 months) and the high SINS group (median survival: 5.3 months; <span class="html-italic">p</span> = 0.023).</p>
Full article ">Figure 3
<p>Surgical complications across the low-to-moderate and high SINS groups.</p>
Full article ">
13 pages, 2705 KiB  
Article
Prognostic Role of Lymphocyte-to-C-Reactive Protein Ratio in Patients with Pulmonary Arterial Hypertension
by Meng-Qi Chen, Chuan-Xue Wan, Jun Tong, An Wang, Bin-Qian Ruan and Jie-Yan Shen
J. Clin. Med. 2024, 13(24), 7855; https://doi.org/10.3390/jcm13247855 - 23 Dec 2024
Abstract
Background: Inflammation plays a critical role in the prognosis of patients with pulmonary arterial hypertension (PAH). The lymphocyte-to-C-reactive protein ratio (LCR), as a novel inflammatory marker, has not been studied in patients with PAH. The objective of this study was to investigate the [...] Read more.
Background: Inflammation plays a critical role in the prognosis of patients with pulmonary arterial hypertension (PAH). The lymphocyte-to-C-reactive protein ratio (LCR), as a novel inflammatory marker, has not been studied in patients with PAH. The objective of this study was to investigate the prognostic value of the LCR in patients with PAH. Methods: A retrospective cohort study was conducted on 116 patients with PAH diagnosed in Renji Hospital, School of Medicine, Shanghai Jiao Tong University, from January 2014 to December 2018. The primary outcome was a composite endpoint that included lung transplantation, rehospitalization for PAH, and all-cause death. The LCR is the ratio of the blood lymphocyte count to the C-reactive protein concentration. Results: A total of 116 patients with PAH were included in this study, with an average age of 41.53 years; 92.2% were female, and the event rate was 57.8%. Restricted cubic spline analysis confirmed a linear association between the LCR and the risk of clinical worsening events. Multivariate Cox proportional hazards analysis showed that the LCR was significantly negatively associated with clinical worsening events, with hazard ratios and 95% confidence intervals of 0.772 (0.614–0.970). The Kaplan–Meier curve showed that event-free survival decreased significantly when the LCR was less than 1.477. LASSO regression selected four potential predictors, including the LCR, to construct a nomogram. The nomogram had a high predictive strength, with an area under the ROC curve of 0.805 (0.713–0.896). The calibration curves and decision curve analysis indicated that the nomogram had good predictive performance and the ability to guide clinical management. Conclusions: The LCR is a valuable prognostic marker for predicting long-term clinical events in patients with PAH, and the nomogram incorporating the LCR could effectively stratify risk and guide clinical decision making. Full article
(This article belongs to the Special Issue Clinical Insights into Pulmonary Hypertension)
Show Figures

Figure 1

Figure 1
<p>Restricted cubic spline analysis of LCR and risk of clinical worsening events in patients with PAH. Changes in hazard ratios for 1-year (<b>A</b>), 3-year (<b>B</b>), and 5-year (<b>C</b>) clinical worsening events across different baseline levels of the LCR. Hazard ratios and 95% confident intervals were estimated using Cox proportional hazards models. LCR, lymphocyte-to-C-reactive protein ratio; PAH, pulmonary arterial hypertension.</p>
Full article ">Figure 2
<p>Kaplan–Meier survival analysis of LCR and the risk of clinical worsening events in patients with PAH. The LCR was expressed as a categorical variable according to optimal <span class="html-italic">p</span>-value method: LCR &lt; 1.477 and LCR ≥ 1.477. Differences between the two groups were compared using the log-rank test. LCR, lymphocyte-to-C-reactive protein ratio; PAH, pulmonary arterial hypertension.</p>
Full article ">Figure 3
<p>Selection of potential predictors of LASSO regression in patients with PAH. (<b>A</b>) The coefficient shrinkage process for 28 variables, with colored lines representing the changes in coefficients of different features at various levels of shrinkage. (<b>B</b>) A 10-fold cross-validation to determine the optimal penalty parameter lambda. A vertical line is drawn at the point of 1 standard error (1-SE) of the minimum criterion. LASSO, least absolute shrinkage and selection operator; PAH, pulmonary arterial hypertension.</p>
Full article ">Figure 4
<p>Nomogram for clinical worsening events prediction in patients with PAH. The nomogram was based on Cox proportional hazards models, integrating four variables: lymphocyte-to-C-reactive protein ratio (LCR), PAH subtype (subgroups), 6 min walk distance (6MWD), and WHO cardiac functional class (WHO-FC). PAH, pulmonary arterial hypertension.</p>
Full article ">Figure 5
<p>Receiver operating characteristic curves of four models for 1-year (<b>A</b>), 3-year (<b>B</b>) and 5-year (<b>C</b>) clinical worsening events. The dotted line represents the reference line. Clinical model included variables of PAH subtype, 6 min walk distance, and WHO cardiac functional class. European Society of Cardiology (ESC) model included variables of B-type natriuretic peptide, 6 min walk distance, and WHO cardiac functional class.</p>
Full article ">Figure 6
<p>Validation of the four models through calibration curve and decision curve analysis. (<b>A</b>–<b>C</b>) Calibration curves of the four models for 1-year (<b>A</b>), 3-year (<b>B</b>), and 5-year (<b>C</b>) clinical worsening events, with the x-axes representing actual event probabilities and the y-axes representing predicted event probabilities. The dotted line represents the ideal prediction. (<b>D</b>–<b>F</b>) Decision curve analysis of the four models for 1-year (<b>D</b>), 3-year (<b>E</b>), and 5-year (<b>F</b>) clinical worsening events. Clinical model includes variables of PAH subtype, 6 min walk distance, and WHO cardiac functional class. European Society of Cardiology (ESC) model includes variables of B-type natriuretic peptide, 6 min walk distance, and WHO cardiac functional class.</p>
Full article ">
14 pages, 2192 KiB  
Article
Heat-Killed Lactobacillus delbrueckii subsp. lactis 557 Extracts Protect Chondrocytes from Osteoarthritis Damage by Reducing Inflammation: An In Vitro Study
by Yu-Chen Hu, Tzu-Ching Huang, Bau-Shan Hsieh, Li-Wen Huang, Jin-Seng Lin, Han-Yin Hsu, Chia-Chia Lee and Kee-Lung Chang
Nutrients 2024, 16(24), 4417; https://doi.org/10.3390/nu16244417 - 23 Dec 2024
Abstract
Background: Osteoarthritis (OA) is a chronic condition characterized by joint pain and disability, driven by excessive oxidative stress and inflammatory cytokine production in chondrocytes, resulting in cell death and cartilage matrix breakdown. Our previous study showed that in monosodium iodoacetate (MIA)-induced OA rats, [...] Read more.
Background: Osteoarthritis (OA) is a chronic condition characterized by joint pain and disability, driven by excessive oxidative stress and inflammatory cytokine production in chondrocytes, resulting in cell death and cartilage matrix breakdown. Our previous study showed that in monosodium iodoacetate (MIA)-induced OA rats, oral administration of heat-killed Lactobacillus delbrueckii subsp. lactis 557 (LDL557) could significantly decrease OA progression. Methods: Accordingly, we designed an in vitro cell culture study aimed at investigating the effects of heat-killed LDL557 extracts on chondrocytes using SW1353 cells (a human chondrosarcoma cell line) challenged with 5 μM MIA to mimic OA conditions. Results: The results showed that the 10 μg/mL LDL557 extracts protected SW1353 cells from MIA-induced death and reduced extracellular matrix (ECM) loss, as evaluated by toluidine blue O staining and extracellular matrix component synthesis with RT-qPCR measurement. This was achieved by decreasing the expression of MIA-induced pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α, while slightly increasing the MIA-suppressed expression of the anti-inflammatory cytokine IL-10, which were evidenced by RT-qPCR analysis. Moreover, the RT-qPCR evaluation also indicated that the LDL557 extracts slightly reduced the expression of COX-2 compared with the control, while it did not reduce the MIA-increased expression of microsomal prostaglandin E synthase-1 (mPGES-1). In addition, the LDL557 extracts influenced neither the matrix-degrading protease expressions measured via RT-qPCR nor the oxidative stress measured via fluorescence flow cytometry in the cells with or without the MIA challenge. Conclusions: This study demonstrates that LDL557 extracts may protect chondrocytes from OA damage by reducing inflammation-related factors and thus mitigating cartilage matrix loss, suggesting LDL557 extracts are attractive alternatives for OA applications. Full article
(This article belongs to the Special Issue Functional Foods and Sustainable Health (2nd Edition))
Show Figures

Figure 1

Figure 1
<p>Effects of LDL557 extracts (LDL557) on SW1353 cell viability and monosodium iodoacetate (MIA, M)-induced cell death. The SW1353 cells were incubated for 24 h in the absence or presence of LDL557 extracts in the range of 3–200 μg/mL (<b>A</b>), or the cells were treated with 10 μg/mL LDL557 extracts for 24 h, followed by incubation with or without 5 μM MIA for an additional 24 h. Then, cell viability was determined via crystal violet staining (<b>B</b>). Data are presented as a percentage of the control group, accompanied by the mean ± standard deviation (S.D.) from three experiments. Statistically significant differences are indicated by * (<span class="html-italic">p</span> &lt; 0.05 compared with the untreated control group) and # (<span class="html-italic">p</span> &lt; 0.05 compared with the MIA-treated group). C = control untreated cells; M = MIA-treated cells; LDL557 = cells treated only with LDL557 extracts; M+LDL557 = cells treated with LDL557 extracts followed by treatment with MIA.</p>
Full article ">Figure 2
<p>The effects of LDL557 extracts or MIA on extracellular matrix component synthesis. The details of the treatment with LDL557 extracts and MIA are described in <a href="#sec2dot4-nutrients-16-04417" class="html-sec">Section 2.4</a> and <a href="#sec2dot5-nutrients-16-04417" class="html-sec">Section 2.5</a>. The acidic glycosaminoglycan contents were determined through toluidine blue O staining (<b>A</b>). The mRNA levels of collagen type II (<b>B</b>), aggrecan (<b>C</b>), and SOX9 (<b>D</b>) were analyzed using RT-qPCR, with β-actin as the internal control. Results are presented as fold changes relative to the untreated control. Data are presented as a percentage of the control group, accompanied by the mean ± standard deviation (S.D.) from three experiments. Statistically significant differences are indicated by * (<span class="html-italic">p</span> &lt; 0.05 compared with the untreated control group) and # (<span class="html-italic">p</span> &lt; 0.05 compared with the MIA-treated group). C = control untreated cells; M = MIA-treated cells; LDL557 = cells treated only with LDL557 extracts; M+LDL557 = cells treated with LDL557 extracts followed by treatment with MIA.</p>
Full article ">Figure 3
<p>The effects of LDL557 extracts or MIA on matrix metalloproteinase (MMP) mRNA expression. The details of the treatment with LDL557 extracts and MIA are described in <a href="#sec2dot5-nutrients-16-04417" class="html-sec">Section 2.5</a>. The expressions of MMP-1 (<b>A</b>), MMP-3 (<b>B</b>), MMP-9 (<b>C</b>), MMP-13 (<b>D</b>), TIMP-1 (<b>E</b>), TIMP-3 (<b>F</b>), ADAMTS-4 (<b>G</b>), and ADAMTS-5 (<b>H</b>) were assayed via RT-qPCR with β-actin as the internal control. Results are presented as fold changes relative to the untreated control. Data are presented as the fold change of the control group accompanied by the mean ± standard deviation (S.D.) from three experiments. Statistically significant differences are indicated by * (<span class="html-italic">p</span> &lt; 0.05 compared with the untreated control group). C = control untreated cells; M = MIA-treated cells; LDL557 = cells treated only with LDL557 extracts; M+LDL557 = cells treated with LDL557 extracts followed by treatment with MIA.</p>
Full article ">Figure 4
<p>Oxidative stress of SW1353 cells treated with LDL557 extracts or MIA. The details of the treatment with LDL557 extracts and MIA are described in <a href="#sec2dot6-nutrients-16-04417" class="html-sec">Section 2.6</a>, and flow cytometry was conducted to analyze the levels of ROS (<b>A</b>), H<sub>2</sub>O<sub>2</sub> (<b>B</b>), and NO (<b>C</b>) using DCFH-DA, MitoPY1, and DAF-FM DA staining, respectively. The untreated control is depicted by the color-filled area (yellow, blue, or green), while the treated groups are represented by the thick black lines. Data are presented as a percentage of the control group, accompanied by the mean ± standard deviation (S.D.) from three experiments. Statistically significant differences are indicated by * (<span class="html-italic">p</span> &lt; 0.05 compared with the untreated control group). C = control untreated cells; M = MIA-treated cells; LDL557 = cells treated only with LDL557 extracts; M+LDL557 = cells treated with LDL557 extracts followed by treatment with MIA.</p>
Full article ">Figure 5
<p>Effects of LDL557 extracts or MIA on inflammatory and anti-inflammatory cytokines’ mRNA expression in SW1353 cells. The details of the treatment with LDL557 extracts and MIA are described in <a href="#sec2dot5-nutrients-16-04417" class="html-sec">Section 2.5</a>. The mRNA expression levels of IL-1β (<b>A</b>), IL-6 (<b>B</b>), TNF-α (<b>C</b>), and IL-10 (<b>D</b>) were analyzed via RT-qPCR with β-actin used as the internal control. Data are presented as a fold change of the control group, accompanied by the mean ± standard deviation (S.D.) from three experiments. Statistically significant differences are indicated by * (<span class="html-italic">p</span> &lt; 0.05 compared with the untreated control group) and # (<span class="html-italic">p</span> &lt; 0.05 compared with the MIA-treated group). C = control untreated cells; M = MIA-treated cells; LDL557 = cells treated only with LDL557 extracts; M+LDL557 = cells treated with LDL557 extracts followed by treatment with MIA.</p>
Full article ">Figure 6
<p>Effects of LDL557 extracts or MIA on COX-2 and mPGES-1 mRNA expression in SW1353 cells. The details of the treatment with LDL557 extracts and MIA are described in <a href="#sec2dot5-nutrients-16-04417" class="html-sec">Section 2.5</a>. The mRNA expressions of COX-2 (<b>A</b>) and mPGES-1 (<b>B</b>) were measured with β-actin used as the internal control. Data are presented as a fold change of the control group, accompanied by the mean ± standard deviation (S.D.) from three experiments. Statistically significant differences are indicated by * (<span class="html-italic">p</span> &lt; 0.05 compared with the untreated control group). C = control untreated cells; M = MIA-treated cells; LDL557 = cells treated only with LDL557 extracts; M+LDL557 = cells treated with LDL557 extracts followed by treatment with MIA.</p>
Full article ">
9 pages, 1252 KiB  
Article
Liver Stiffness, Not Steatosis, Predicts Mortality in MASLD Patients: An NHANES Analysis
by Yuting Huang, Yichen Wang, Yan Yan, Samuel O. Antwi, Dilhana S. Badurdeen and Liu Yang
Livers 2024, 4(4), 711-719; https://doi.org/10.3390/livers4040049 - 23 Dec 2024
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has surged as a major cause of liver transplants in the United States. Existing studies have presented conflicting findings regarding the association between liver characteristics (specifically steatosis and fibrosis) and mortality. This study investigates the relationship [...] Read more.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has surged as a major cause of liver transplants in the United States. Existing studies have presented conflicting findings regarding the association between liver characteristics (specifically steatosis and fibrosis) and mortality. This study investigates the relationship between the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE) and all-cause mortality in MASLD patients. Methods: Using the NHANES 2017-2018 database, 3821 individuals representing the United States population with MASLD underwent VCTE for liver stiffness measurement. Exclusion criteria were applied, eliminating ineligible cases, incomplete examinations, underage individuals, and those with hepatitis B or C, along with significant alcohol consumption history. Cox proportional hazard models assessed the hazard ratio (HR) for all-cause mortality in CAP and LSM. Cox regression analysis with interaction terms was employed for deeper exploration. Results: The study unveiled a strong, independent correlation between LSM and all-cause mortality. However, the CAP failed to demonstrate a significant association with mortality in both univariate and adjusted analyses, contrary to recent findings. The analysis underscores the importance of accurately measuring liver stiffness via VCTE in predicting adverse outcomes in MASLD patients, emphasizing the pivotal role of fibrosis in assessing mortality risk. Conclusion: This study reaffirms the robust link between liver fibrosis (measured through VCTE) and mortality among MASLD individuals. The absence of a significant association between steatosis (indicated by CAP) and mortality challenges recent research, urging further comprehensive investigations with larger cohorts to delineate steatosis’ precise impact on MASLD-related mortality. Full article
Show Figures

Figure 1

Figure 1
<p>Study design and participant flowchart. Flowchart depicting the study design and participant selection process. A total of 9254 patients were initially considered. After excluding 2853 patients ineligible for VCTE, 6401 were eligible. Of these, 907 had incomplete examinations and were excluded, leaving 5494 participants with completed VCTE. Further exclusions were made for participants under 18 years of age (n = 867), with positive HBsAg (n = 27), positive HCV RNA (n = 43), and alcohol use history (n = 736), resulting in a final study cohort of 3821 participants.</p>
Full article ">Figure 2
<p>Kaplan–Meier survival curves for mortality stratified by CAP and LSM percentiles. Kaplan–Meier survival estimates stratified by (<b>A</b>) controlled attenuation parameter (CAP) and (<b>B</b>) liver stiffness measurement (LSM) percentiles. Groups are divided into below the 90th percentile (&lt;90th) and above the 90th percentile (≥90th). Numbers in the risk table are weighted estimates after applying sampling weights. The hazard ratio (HR), 95% confidence interval (CI), and <span class="html-italic">p</span>-value by log-rank tests are as follows: CAP (HR 1.57, 95% CI: 0.61–4.02, <span class="html-italic">p</span> = 0.351), LSM (HR 2.42, 95% CI: 1.05–5.55, <span class="html-italic">p</span> = 0.037).</p>
Full article ">Figure 3
<p>Three-dimensional contour plot illustrating the interrelationship between LSM, CAP, and the risk of all-cause mortality. The plot is based on a multivariate Cox regression model, in which LSM and CAP are handled as continuous variables. The <span class="html-italic">p</span> values are represented along the Z-axis, while the hazard ratios are color-coded, offering an integrative perspective of the simultaneous influences of LSM and CAP on the risk of all-cause mortality. Abbreviations: CAP (controlled attenuation parameter) is a noninvasive technique for determining hepatic steatosis; LSM (liver stiffness measurement) is a noninvasive indicator of liver fibrosis.</p>
Full article ">
22 pages, 576 KiB  
Article
Exploring the Relationship Between Ejection Fraction, Arterial Stiffness, NT-proBNP, and Hospitalization Risk in Heart Failure Patients
by Gyongyi Osser, Brigitte Osser, Csongor Toth, Caius Calin Miuța, Gabriel Roberto Marconi and Laura Ioana Bondar
Diagnostics 2024, 14(24), 2885; https://doi.org/10.3390/diagnostics14242885 - 22 Dec 2024
Viewed by 171
Abstract
Background/Objectives: Heart failure (HF) remains a leading cause of hospitalization and morbidity. Arterial stiffness, measured by pulse wave velocity (PWV) and the augmentation index (AIx), has been linked to HF severity and prognosis. This study investigates the relationship between clinical parameters, biochemical indicators, [...] Read more.
Background/Objectives: Heart failure (HF) remains a leading cause of hospitalization and morbidity. Arterial stiffness, measured by pulse wave velocity (PWV) and the augmentation index (AIx), has been linked to HF severity and prognosis. This study investigates the relationship between clinical parameters, biochemical indicators, and arterial stiffness in hospitalized patients with HF, aiming to identify predictors of hospitalization and improve patient management. Methods: This cross-sectional study included 98 patients admitted with HF: 53 with acutely decompensated HF (sudden worsening of symptoms) and 45 with chronic HF (stable symptoms of HF). Clinical and biochemical parameters, including ejection fraction (EF), N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels, and arterial stiffness indicators (PWV and AIx), were measured at admission. During follow-up, 59 patients required re-hospitalization due to acutely decompensated HF, while 39 remained outpatients without further hospitalization. The relationship between these parameters was analyzed using Pearson correlation coefficients, and multiple Cox regression analysis was conducted to identify independent predictors of re-hospitalization. Results: A significant negative correlation between EF and PWV was found (r = −0.853, 95% CI [−0.910, −0.764]), suggesting an association between improved heart function (higher EF) and reduced arterial stiffness (lower PWV). A moderate positive correlation between EF and AIx (r = 0.626, 95% CI [0.473, 0.805]) suggests that, while higher EF is associated with increased AIx, the relationship is weaker compared to EF and PWV. This may reflect differing contributions of vascular and myocardial factors to HF severity. Hospitalized patients exhibited significantly poorer clinical and biochemical profiles, including higher NT-proBNP levels (p < 0.001) and worse blood pressure (BP) measurements (systolic and diastolic, p < 0.01). Multiple Cox regression analysis identified PWV, Aix, and NT-proBNP as independent predictors of re-hospitalization in HF patients, with significant hazard ratios: PWV (HR = 1.15, p = 0.02), AIx (HR = 1.03, p = 0.02), and NT-proBNP (HR = 1.0001, p < 0.01). Conclusions: Arterial stiffness indices (PWV and AIx), EF, and NT-proBNP were identified as significant predictors of re-hospitalization in HF patients. These findings suggest that integrating arterial stiffness measurements into routine clinical assessments may enhance the risk stratification and inform targeted interventions to reduce hospitalizations and improve outcomes. Full article
(This article belongs to the Section Clinical Diagnosis and Prognosis)
Show Figures

Figure 1

Figure 1
<p>Correlation of the arterial stiffness markers (PWV and AIx) with EF in hospitalized patients (<span class="html-italic">n</span> = 59). (<b>a</b>) Correlation between PWV and EF. (<b>b</b>) Correlation between AIx and EF.</p>
Full article ">
13 pages, 3232 KiB  
Article
Eremophilane- and Acorane-Type Sesquiterpenes from the Deep-Sea Cold-Seep-Derived Fungus Furcasterigmium furcatum CS-280 Cultured in the Presence of Autoclaved Pseudomonas aeruginosa QDIO-4
by Xiao-Dan Chen, Xin Li, Xiao-Ming Li, Sui-Qun Yang and Bin-Gui Wang
Mar. Drugs 2024, 22(12), 574; https://doi.org/10.3390/md22120574 - 22 Dec 2024
Viewed by 205
Abstract
Six new sesquiterpenes, including four eremophilane derivatives fureremophilanes A–D (14) and two acorane analogues furacoranes A and B (5 and 6), were characterized from the culture extract of the cold-seep derived fungus Furcasterigmium furcatum CS-280 co-cultured with [...] Read more.
Six new sesquiterpenes, including four eremophilane derivatives fureremophilanes A–D (14) and two acorane analogues furacoranes A and B (5 and 6), were characterized from the culture extract of the cold-seep derived fungus Furcasterigmium furcatum CS-280 co-cultured with autoclaved Pseudomonas aeruginosa QDIO-4. All the six compounds were highly oxygenated especially 2 and 3 with infrequent epoxyethane and tetrahydrofuran ring systems. The structures of 16 were established on the basis of detailed interpretation of 1D and 2D NMR and MS data. Their relative and absolute configurations were assigned by a combination of NOESY and single crystal X-ray crystallographic analysis, and by time-dependent density functional (TDDFT) ECD calculations as well. All compounds were tested the anti-inflammatory activity against human COX-2 protein, among which, compounds 2 and 3 displayed activities with IC50 values 123.00 µM and 93.45 µM, respectively. The interaction mechanism was interpreted by molecular docking. Full article
(This article belongs to the Special Issue Bioactive Natural Products from the Deep-Sea-Sourced Microbes)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Chemical Structures of Compounds <b>1</b>–<b>6</b>.</p>
Full article ">Figure 2
<p>Key HMBC (arrows) and COSY (bold lines) correlations for compounds <b>1</b>–<b>6</b>.</p>
Full article ">Figure 3
<p>X-ray crystallographic structures of compounds <b>1</b>, <b>3</b>, and <b>4</b>.</p>
Full article ">Figure 4
<p>Key NOE correlations observed for compounds <b>2</b>, <b>3</b>, and <b>5</b> (red and blue arrows represent α- and β-orientations, respectively).</p>
Full article ">Figure 5
<p>Experimental (black) and calculated (red) ECD spectra of compound <b>6</b>.</p>
Full article ">Figure 6
<p>The inhibitory effects (IC<sub>50</sub>) of celecoxib and compounds <b>2</b> and <b>3</b> toward COX-2. (<b>A</b>) Celecoxib (positive control): 42.18 nM. (<b>B</b>) Compound <b>2</b>: 123.00 μM. (<b>C</b>) Compound <b>3</b>: 93.45 μM.</p>
Full article ">Figure 7
<p>Molecular docking simulation results: (<b>A</b>) Compounds <b>1</b>–<b>4</b> and celecoxib interacted with 5IKR (<b>1</b> in red, <b>2</b> in blue, <b>3</b> in pink, <b>4</b> in green, celecoxib in yellow); (<b>B</b>) Compound <b>2</b> interacted with 5IKR; (<b>C</b>) Compound <b>3</b> interacted with 5IKR; (<b>D</b>) Compound <b>3</b> and celecoxib interacted with 5IKR.</p>
Full article ">
21 pages, 4110 KiB  
Article
Succinate Regulates Endothelial Mitochondrial Function and Barrier Integrity
by Reham Atallah, Juergen Gindlhuber, Wolfgang Platzer, Rishi Rajesh and Akos Heinemann
Antioxidants 2024, 13(12), 1579; https://doi.org/10.3390/antiox13121579 (registering DOI) - 21 Dec 2024
Viewed by 317
Abstract
Endothelial dysfunction is a hallmark of several pathological conditions, including cancer, cardiovascular disease and inflammatory disorders. In these conditions, perturbed TCA cycle and subsequent succinate accumulation have been reported. The role of succinate as a regulator of immunological responses and inflammation is increasingly [...] Read more.
Endothelial dysfunction is a hallmark of several pathological conditions, including cancer, cardiovascular disease and inflammatory disorders. In these conditions, perturbed TCA cycle and subsequent succinate accumulation have been reported. The role of succinate as a regulator of immunological responses and inflammation is increasingly being recognized. Nevertheless, how endothelial cell function and phenotype are altered by elevated intracellular succinate has not been addressed yet. Thus, we employed numerous in vitro functional assays using primary HUVECs and diethyl succinate (DES), a cell membrane-permeable succinate analogue. An MTS assay 1 h post stimulation with DES suggested reduced metabolic activity in HUVECs. Concurrently, elevated production of ROS, including mitochondrial superoxide, and a reduction in mitochondrial membrane potential were observed. These findings were corroborated by Seahorse mito-stress testing, which revealed that DES acutely lowered the OCR, maximal respiration and ATP production. Given the link between mitochondrial stress and apoptosis, we examined important survival signalling pathways. DES transiently reduced ERK1/2 phosphorylation, a response that was followed by a skewed pro-apoptotic shift in the BAX to BCL2L1 gene expression ratio, which coincided with upregulating VEGF gene expression. This indicated an induction of mixed pro-apoptotic and pro-survival signals in the cell. However, the BAX/BCL-XL protein ratio was unchanged, suggesting that the cells did not commit themselves to apoptosis. An MTS assay, caspase 3/7 activity assay and annexin V/propidium iodide staining confirmed this finding. By contrast, stimulation with DES induced acute endothelial barrier permeability, forming intercellular gaps, altering cell size and associated actin filaments without affecting cell count. Notably, during overnight DES exposure gradual recovery of the endothelial barrier and cell sprouting was observed, alongside mitochondrial membrane potential restoration, albeit with sustained ROS production. COX-2 inhibition and EP4 receptor blockade hindered barrier restoration, implicating a role of COX-2/PGE2/EP4 signalling in this process. Interestingly, ascorbic acid pre-treatment prevented DES-induced acute barrier disruption independently from ROS modulation. In conclusion, succinate acts as a significant regulator of endothelial mitochondrial function and barrier integrity, a response that is counterbalanced by upregulated VEGF and prostaglandin production by the endothelial cells. Full article
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Effect of DES on metabolic and mitochondrial function in HUVECs. (<b>A</b>) MTS assay of HUVECs stimulated with DES at indicated concentrations for 1 h (n = 3). (<b>B</b>) DHR 123 geometric mean of fluorescence intensity in HUVECs stimulated with DES at indicated concentrations for selected time points (n = 5). (<b>C</b>) MitoSOX geometric mean of fluorescence intensity in HUVECs stimulated with DES at indicated concentrations for selected time points (n = 3). (<b>D</b>) TMRE geometric mean of fluorescence intensity in HUVECs stimulated with DES at indicated concentrations for selected time points (n = 4). For (<b>B</b>–<b>D</b>), the dotted line refers to vehicle-treated cells. (<b>E</b>) Representative microscopic image for 3 independent experiments with TMRE in HUVECs stimulated with 10 mM DES for indicated times. (<b>F</b>) Mito-stress assay of HUVECs demonstrating OCR with sequential addition of treatments. Acute response to DES, maximal respiration and ATP production were calculated (n = 5). For (<b>A</b>–<b>D</b>,<b>F</b>), data are presented as mean and SEM, with statistical significance determined using two-way ANOVA for repeated measures followed by Tukey’s post hoc test (<b>B</b>–<b>D</b>) or one-way ANOVA for repeated measures followed by Tukey’s post hoc test (<b>A</b>,<b>F</b>). For (<b>C</b>,<b>D</b>), * refers to comparison between vehicle and 10 mM DES, while # refers to comparison between vehicle and 5 mM DES. *, # <span class="html-italic">p</span> &lt; 0.05; **, ## <span class="html-italic">p</span> &lt; 0.01; *** <span class="html-italic">p</span> &lt; 0.001; **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 2
<p>Effect of DES on HUVECs viability. (<b>A</b>) Western blot of phosphorylated ERK1/2 and ratio of pERK/tERK/β-actin in HUVECs stimulated with 10 mM DES for indicated time points (n = 4). (<b>B</b>) RT-PCR of BAX, BCL2L1 and VEGF mRNA expression in HUVECs stimulated with 10 mM DES for 4 h (n = 5). (<b>C</b>) Western blot of BAX and BCL-XL in HUVECs stimulated with 10 mM DES for 6 h (n = 5). (<b>D</b>) MTS assay of HUVECs stimulated with indicated DES concentrations for 6 h (n = 3). (<b>E</b>) Caspase 3/7 activity of HUVECs post treatment with indicated DES concentrations for 16 h (n = 3). (<b>F</b>) Representative dot plot of annexin V/propidium iodide staining of HUVECs treated with indicated DES concentrations for 16 h. Live and apoptotic cells were quantified (n = 9). Data are presented as mean and SEM, with statistical significance determined using one-way ANOVA for repeated measures followed by Tukey’s post hoc test (<b>A</b>,<b>D</b>–<b>F</b>) or paired <span class="html-italic">t</span>-test (<b>B</b>,<b>C</b>). * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01; *** <span class="html-italic">p</span> &lt; 0.001; **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 3
<p>Acute effect of DES on HUVECs barrier integrity. (<b>A</b>) Resistance of HUVECs monolayer stimulated with DES at indicated concentrations (n = 4). (<b>B</b>) Immunofluorescence staining of VE-cadherin and F-actin in HUVECs stimulated with 10 mM DES at selected time points. The image is representative of 3 independent experiments. Zoomed-in images are shown on the upper right side for each condition, scale bar = 50 µm. (<b>C</b>) Image analysis demonstrating number of nuclei, gap size, average cell size and median fluorescence intensity (MFI) of phalloidin-stained stress fibres. Data are presented as mean and SEM, with statistical significance determined using two-way ANOVA for repeated measures followed by Tukey’s post hoc test (<b>A</b>) or one-way ANOVA for repeated measures followed by Tukey’s post hoc test (<b>C</b>). For (<b>A</b>), * refers to comparison between vehicle and 10 mM DES, while # refers to comparison between vehicle and 5 mM DES. * <span class="html-italic">p</span> &lt; 0.05; **, ## <span class="html-italic">p</span> &lt; 0.01; ***, ### <span class="html-italic">p</span> &lt; 0.001; **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 4
<p>Restoration of HUVECs barrier and sprouting during overnight stimulation with DES. (<b>A</b>) Resistance of HUVECs monolayer with overnight stimulation with DES at indicated concentrations (n = 6). (<b>B</b>) Spheroid sprouting assay of HUVECs stimulated with 10 mM DES for 16 h. Number of sprouts and total sprout length were calculated. The image is representative of three independent experiments. (<b>C</b>) Western blot of HIF-1α in HUVECs stimulated with DES at indicated concentrations for 16 h (n = 8). (<b>D</b>) Western blot of phosphorylated ERK1/2 and ratio of pERK/tERK/β-actin in HUVECs stimulated with indicated DES concentrations for 16 h (n = 4). (<b>E</b>) MTS assay of HUVECs stimulated with DES at indicated concentrations for 16 h (n = 3). (<b>F</b>) DHR 123 geometric mean of fluorescence intensity in HUVECs stimulated with DES at indicated concentrations for 16 h (n = 6). (<b>G</b>) MitoSOX geometric mean of fluorescence intensity in HUVECs stimulated with DES at indicated concentrations for 16 h (n = 5). (<b>H</b>) TMRE geometric mean of fluorescence intensity in HUVECs stimulated with DES at indicated concentrations for 16 h (n = 4). Data are presented as mean and SEM, with statistical significance determined using two-way ANOVA for repeated measures followed by Tukey’s post hoc test (<b>A</b>), paired <span class="html-italic">t</span>-test (<b>B</b>) or one-way ANOVA for repeated measures followed by Tukey’s post hoc test (<b>C</b>–<b>H</b>). ns refers to no statistical difference between vehicle and either 5 mM DES or 10 mM DES. * <span class="html-italic">p</span> &lt; 0.05; *** <span class="html-italic">p</span> &lt; 0.001; **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 5
<p>COX-2/PGE<sub>2</sub>/EP4 contribution to barrier recovery in HUVECs. (<b>A</b>) Western blot of COX-2 in HUVECs after 16 h of stimulation with DES at indicated concentrations (n = 6). (<b>B</b>) Radioimmunoassay for quantification of PGE<sub>2</sub> in supernatants of HUVECs stimulated with DES for 16 h (n = 3). (<b>C</b>) Resistance of HUVECs monolayer treated with diclofenac ~1 h prior to stimulation with 10 mM DES (n = 3). (<b>D</b>) Resistance of HUVECs monolayer stimulated with PGE<sub>2</sub> (n = 3). (<b>E</b>) Resistance of HUVECs monolayer treated with EP2 antagonist ~2 h post treatment with 10 mM DES (n = 3). (<b>F</b>) Resistance of HUVECs monolayer treated with EP4 antagonist ~2 h post treatment with 10 mM DES (n = 3). Data are presented as mean and SEM, with statistical significance determined using one-way ANOVA for repeated measures followed by Tukey’s post hoc test (<b>A</b>,<b>B</b>) or two-way ANOVA for repeated measures followed by Tukey’s post hoc test (<b>C</b>–<b>F</b>). * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01; **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 6
<p>Ascorbic acid prevention of initial barrier drop induced by DES in HUVECs. (<b>A</b>) Resistance of HUVECs monolayer treated with ascorbic acid at demonstrated concentrations 15 min prior to stimulation with DES at indicated concentrations (n = 4). (<b>B</b>) DHR 123 geometric mean of fluorescence intensity in HUVECs stimulated with DES at indicated concentrations for 1 h with/without 15 min of ascorbic acid pre-treatment (n = 3). (<b>C</b>) MitoSOX geometric mean of fluorescence intensity in HUVECs stimulated with DES at indicated concentrations for 1 h with/without 15 min of ascorbic acid pre-treatment (n = 3). Data are presented as mean and SEM, with statistical significance determined using two-way ANOVA for repeated measures followed by Tukey’s post hoc test (<b>A</b>) or one-way ANOVA for repeated measures followed by Tukey’s post hoc test (<b>B</b>,<b>C</b>). For (<b>A</b>), * refers to comparison between 10 mM DES and AA + 10 mM DES, while # refers to comparison between 5 mM DES and AA + 5 mM DES. *, # <span class="html-italic">p</span> &lt; 0.05; **, ## <span class="html-italic">p</span> &lt; 0.01; **** <span class="html-italic">p</span> &lt; 0.0001. AA denotes ascorbic acid.</p>
Full article ">
18 pages, 3444 KiB  
Review
Search for New Compounds with Anti-Inflammatory Activity Among 1,2,4-Triazole Derivatives
by Teresa Glomb, Julia Minta, Michalina Nowosadko, Julia Radzikowska and Piotr Świątek
Molecules 2024, 29(24), 6036; https://doi.org/10.3390/molecules29246036 - 21 Dec 2024
Viewed by 275
Abstract
Compounds containing the 1,2,4-triazole moiety in their structure exhibit broad biological activities. Many of these compounds demonstrate anti-inflammatory activity in vitro through various mechanisms, such as inhibiting COX-1/COX-2 and LOX, modulating pro-inflammatory cytokine levels, or having effects on other specific enzymes. Some also [...] Read more.
Compounds containing the 1,2,4-triazole moiety in their structure exhibit broad biological activities. Many of these compounds demonstrate anti-inflammatory activity in vitro through various mechanisms, such as inhibiting COX-1/COX-2 and LOX, modulating pro-inflammatory cytokine levels, or having effects on other specific enzymes. Some also display activities in vivo. In many publications, the activities of new 1,2,4-triazole-based compounds exceed those of the reference drugs, suggesting their promising potential as new therapeutic agents. This review of active 1,2,4-triazole derivatives with anti-inflammatory activity is based on literature published from 2015–2024. Full article
Show Figures

Figure 1

Figure 1
<p>Examples of known drugs containing a 1,2,4-triazole ring.</p>
Full article ">Figure 2
<p>1,2,4-triazole derivatives as COX inhibitors (part 1).</p>
Full article ">Figure 3
<p>1,2,4-triazole derivatives as COX inhibitors (part 2).</p>
Full article ">Figure 4
<p>1,2,4-triazole derivatives as COX inhibitors (part 3).</p>
Full article ">Figure 5
<p>1,2,4-triazole derivatives as COX inhibitors with sulfamoylphenyl or methylsulfonylphenyl substituents.</p>
Full article ">Figure 6
<p>1,2,4-triazole derivatives as 15-LOX inhibitors (part 1).</p>
Full article ">Figure 7
<p>1,2,4-triazole derivatives as 15-LOX inhibitors (part 2).</p>
Full article ">Figure 8
<p>1,2,4-triazole derivatives as FLAP inhibitors.</p>
Full article ">Figure 9
<p>1,2,4-triazole derivatives as COX-2/5-LOX inhibitors (part 1).</p>
Full article ">Figure 10
<p>1,2,4-triazole derivatives as COX-2/5-LOX inhibitors (part 2).</p>
Full article ">Figure 11
<p>1,2,4-triazole derivatives with confirmed anti-inflammatory activity in vivo (part 1).</p>
Full article ">Figure 12
<p>1,2,4-triazole derivatives with confirmed anti-inflammatory activity in vivo (part 2).</p>
Full article ">Figure 13
<p>1,2,4-triazole derivatives with confirmed anti-inflammatory activity in vivo (part 3).</p>
Full article ">Figure 14
<p>1,2,4-triazole derivatives with miscellaneous mechanisms for anti-inflammatory activity (part 1).</p>
Full article ">Figure 15
<p>1,2,4-triazole derivatives with miscellaneous mechanisms for anti-inflammatory activity (part 2).</p>
Full article ">
20 pages, 3844 KiB  
Article
Inhibition of TFAM-Mediated Mitophagy by Oroxylin A Restored Sorafenib Sensitivity Under Hypoxia Conditions in HepG2 Cells
by Shufan Ji, Xuefen Xu, Yujia Li, Sumin Sun, Qiuyu Fu, Yangling Qiu, Shuqi Wang, Siwei Xia, Feixia Wang, Feng Zhang, Ji Xuan and Shizhong Zheng
Pharmaceuticals 2024, 17(12), 1727; https://doi.org/10.3390/ph17121727 - 20 Dec 2024
Viewed by 236
Abstract
Background: Liver cancer treatment encounters considerable therapeutic challenges, especially because hypoxic microenvironments markedly reduce sensitivity to chemotherapeutic agents. TFAM (mitochondrial transcription factor A) plays a crucial role in maintaining mitochondrial function. Oroxylin A (OA), a flavonoid with potential therapeutic properties, demonstrated prospects in [...] Read more.
Background: Liver cancer treatment encounters considerable therapeutic challenges, especially because hypoxic microenvironments markedly reduce sensitivity to chemotherapeutic agents. TFAM (mitochondrial transcription factor A) plays a crucial role in maintaining mitochondrial function. Oroxylin A (OA), a flavonoid with potential therapeutic properties, demonstrated prospects in cancer treatment. However, the mechanism of the sensitizing effect of OA on cancer cells has not been elucidated. Methods: MTT assays were utilized to evaluate a hypoxia-induced resistance model. Plate colony formation assays, TEM, and JC-1 staining were used to examine the effects of siTFAM on proliferation and mitochondrial damage of HepG2 cells. Cox8-EGFP-mCherry plasmid transfection, LysoTracker and MitoTracker colocalization analysis, and WB were conducted to evaluate the influence of OA on mitophagy. The effect of OA on p53 ubiquitination levels was investigated by Co-IP and the CHX chase assay. A mouse xenograft tumor model was utilized to assess the therapeutic effect of OA on HepG2 cells in vivo. Results: OA significantly improved the inhibitory effect of sorafenib by inhibiting mitophagy on HepG2 cells in in vitro and in vivo models. Notably, the molecular docking and thermal shift assays indicated a clear binding of OA and TFAM. Further research revealed that OA suppressed p53 acetylation and promoted its degradation by downregulating TFAM expression, which ultimately inhibited mitophagy in hypoxia. Conclusions: OA has demonstrated the potential to enhance the efficacy of sorafenib treatment for liver cancer, and TFAM may be one of its targets. Full article
(This article belongs to the Section Natural Products)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>TFAM contributed to hypoxia-induced resistance in HepG2 cells. (<b>A</b>) HepG2 cells were cultured in complete medium containing 50 μM CoCl<sub>2</sub> to establish a hypoxia model. HIF1α levels were assessed and analyzed by Western blot in the presence or absence of CoCl<sub>2</sub> solution. (<b>B</b>) After treatment with sorafenib for 24 h, the impact of sorafenib on HepG2 cell viability was evaluated using an MTT assay under hypoxic and normoxic conditions, respectively. (<b>C</b>) DCFH-DA flow cytometry was employed to measure ROS levels in the presence of sorafenib in hypoxic and normoxic environments. ROS levels under normoxic conditions as a control. (<b>D</b>) With the addition of 2 mmol/L NAC for 1 h under normal conditions, the influence of sorafenib on HepG2 cell viability was determined via the MTT assay. (<b>E</b>) The TCGA database was analyzed to identify differences in TFAM expression between liver cancer tissues and adjacent non-tumor tissues. (<b>F</b>) Patients with high TFAM expression in liver cancer exhibited worse prognosis. (<b>G</b>) RT-PCR showed that TFAM mRNA significantly increased in HepG2 cells under hypoxic conditions. GAPDH mRNA was used to normalize the mRNA level of each gene. (<b>H</b>) TFAM was knocked down by TFAMsiRNA, then HepG2 cells were treated with 10 μM sorafenib for 24 h under hypoxic conditions. DCFH-DA flow cytometry revealed that knockdown of TFAM enhanced the ROS levels in sorafenib-treated HepG2 cells in the resistance model. (<b>I</b>) The plate cloning assay showed that TFAM siRNA significantly decreased colonies of HepG2 cells treated with sorafenib for 24 h under hypoxic conditions. Data are expressed as mean ± SEM. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, and *** <span class="html-italic">p</span> &lt; 0.001 versus control.</p>
Full article ">Figure 1 Cont.
<p>TFAM contributed to hypoxia-induced resistance in HepG2 cells. (<b>A</b>) HepG2 cells were cultured in complete medium containing 50 μM CoCl<sub>2</sub> to establish a hypoxia model. HIF1α levels were assessed and analyzed by Western blot in the presence or absence of CoCl<sub>2</sub> solution. (<b>B</b>) After treatment with sorafenib for 24 h, the impact of sorafenib on HepG2 cell viability was evaluated using an MTT assay under hypoxic and normoxic conditions, respectively. (<b>C</b>) DCFH-DA flow cytometry was employed to measure ROS levels in the presence of sorafenib in hypoxic and normoxic environments. ROS levels under normoxic conditions as a control. (<b>D</b>) With the addition of 2 mmol/L NAC for 1 h under normal conditions, the influence of sorafenib on HepG2 cell viability was determined via the MTT assay. (<b>E</b>) The TCGA database was analyzed to identify differences in TFAM expression between liver cancer tissues and adjacent non-tumor tissues. (<b>F</b>) Patients with high TFAM expression in liver cancer exhibited worse prognosis. (<b>G</b>) RT-PCR showed that TFAM mRNA significantly increased in HepG2 cells under hypoxic conditions. GAPDH mRNA was used to normalize the mRNA level of each gene. (<b>H</b>) TFAM was knocked down by TFAMsiRNA, then HepG2 cells were treated with 10 μM sorafenib for 24 h under hypoxic conditions. DCFH-DA flow cytometry revealed that knockdown of TFAM enhanced the ROS levels in sorafenib-treated HepG2 cells in the resistance model. (<b>I</b>) The plate cloning assay showed that TFAM siRNA significantly decreased colonies of HepG2 cells treated with sorafenib for 24 h under hypoxic conditions. Data are expressed as mean ± SEM. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, and *** <span class="html-italic">p</span> &lt; 0.001 versus control.</p>
Full article ">Figure 2
<p>Silencing TFAM enhanced the sensitivity of HepG2 cells to sorafenib by inhibiting mitophagy. The changes in mitochondria were observed after sorafenib intervention for 24 h in HepG2 cells, with or without TFAM knockdown. (<b>A</b>) Upon TFAM knockdown, the mitochondrial morphology was detected by TEM in sorafenib-treated HepG2 cells under hypoxia conditions. The black arrows indicated normal mitochondria, and the red arrows indicated the damaged mitochondria. The left scale bar: 2.0 μm; the right scale bar: 500 nm. (<b>B</b>) Mitophagy-related proteins (parkin and pink1) were analyzed by Western blot. (<b>C</b>) Flow cytometry measured the effect of TFAM knockdown on MMP levels in hypoxia. HepG2 cells were treated with 5 μM CCCP for 24 h. The experiment was repeated three times. (<b>D</b>) Plate cloning assays showed that combination of 5 μM CCCP and TFAM knockdown under hypoxia conditions significantly promoted the inhibitory effect on cell proliferation. Data are expressed as mean ± SEM, where * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, and *** <span class="html-italic">p</span> &lt; 0.001 denote statistical significance.</p>
Full article ">Figure 3
<p>OA enhanced the sensitivity of HepG2 cells to sorafenib by inhibiting mitophagy. HepG2 cells were treated with different concentrations of OA or 10 μM sorafenib for 24 h under hypoxia conditions. (<b>A</b>) The MTT assay determined the effect of OA on the viability of HepG2 cells. (<b>B</b>) The inhibitory effects of OA (10 μM) and sorafenib (10 μM), either individually or in combination, on HepG2 cells were evaluated under hypoxia conditions. (<b>C</b>) The DCFH-DA assay determined the effect of OA (10 μM) and sorafenib (10 μM), either individually or in combination, on ROS levels. (<b>D</b>) Flow cytometry detected the effect of OA (10 μM) and sorafenib (10 μM), either individually or in combination, on MMP levels. (<b>E</b>) The mitochondrial count was evaluated using Mito-Tracker Red CMXRos after individual or combined treatments. Scale bar: 10 μm. (<b>F</b>) The levels of mitophagy-related proteins were determined by Western blot after individual or combined treatments. (<b>G</b>) HepG2 cells were transiently transfected with the Cox8-EGFP-mCherry plasmid and subsequently treated with OA, either alone or in combination with sorafenib for 24 h. The Cox8-EGFP-mCherry dual fluorescence reporter system was analyzed using confocal microscopy. Both OA treatment alone and the combined treatment with sorafenib markedly enhanced the green fluorescence intensity (EGFP). Scale bar: 2.5 μm. (<b>H</b>) Laser confocal microscopy assessed the colocalization of mitochondria and lysosomes. Scale bar: 10 μm. Data are expressed as mean ± SEM, where * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, and *** <span class="html-italic">p</span> &lt; 0.001 denote statistical significance.</p>
Full article ">Figure 3 Cont.
<p>OA enhanced the sensitivity of HepG2 cells to sorafenib by inhibiting mitophagy. HepG2 cells were treated with different concentrations of OA or 10 μM sorafenib for 24 h under hypoxia conditions. (<b>A</b>) The MTT assay determined the effect of OA on the viability of HepG2 cells. (<b>B</b>) The inhibitory effects of OA (10 μM) and sorafenib (10 μM), either individually or in combination, on HepG2 cells were evaluated under hypoxia conditions. (<b>C</b>) The DCFH-DA assay determined the effect of OA (10 μM) and sorafenib (10 μM), either individually or in combination, on ROS levels. (<b>D</b>) Flow cytometry detected the effect of OA (10 μM) and sorafenib (10 μM), either individually or in combination, on MMP levels. (<b>E</b>) The mitochondrial count was evaluated using Mito-Tracker Red CMXRos after individual or combined treatments. Scale bar: 10 μm. (<b>F</b>) The levels of mitophagy-related proteins were determined by Western blot after individual or combined treatments. (<b>G</b>) HepG2 cells were transiently transfected with the Cox8-EGFP-mCherry plasmid and subsequently treated with OA, either alone or in combination with sorafenib for 24 h. The Cox8-EGFP-mCherry dual fluorescence reporter system was analyzed using confocal microscopy. Both OA treatment alone and the combined treatment with sorafenib markedly enhanced the green fluorescence intensity (EGFP). Scale bar: 2.5 μm. (<b>H</b>) Laser confocal microscopy assessed the colocalization of mitochondria and lysosomes. Scale bar: 10 μm. Data are expressed as mean ± SEM, where * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, and *** <span class="html-italic">p</span> &lt; 0.001 denote statistical significance.</p>
Full article ">Figure 4
<p>OA targeted TFAM to inhibit mitophagy in HepG2 cells. HepG2 cells were treated with OA and 10 μM sorafenib, either individually or in combination, for 24 h under hypoxic conditions. (<b>A</b>) Molecular docking results showed a binding pocket between OA and TFAM in the 3D structure. OA formed hydrogen bonds with TYR211 and LYS145 of TFAM with hydrogen bond lengths of 2.9 and 4.0, respectively. The compound formed hydrophobic interactions with ARG157 and LYS156 of TFAM and π–cation interactions with LYS154 and LYS146 of the protein. (<b>B</b>) Thermal shift assays showed that treatment with OA decreased the degradation rate of TFAM. The thermal melting curve displayed a significant rightward shift following the administration of OA. (<b>C</b>) The effects of OA on TFAM expression were determined and analyzed by Western blot in hypoxia-induced resistance. (<b>D</b>) OA reduced the expression of mitophagy-related proteins in a concentration-dependent manner, which was detected by Western blot. (<b>E</b>) Western blot revealed that either knocking down TFAM or using OA reduced mitophagy-related proteins in HepG2 cells under hypoxia conditions. (<b>F</b>) Western blot analysis indicated that overexpression of TFAM could reverse the OA-mediated inhibition of mitophagy in hypoxia-induced resistant HepG2 cells. (<b>G</b>,<b>I</b>) Laser confocal microscopy analysis revealed that TFAM overexpression could counteract the OA-mediated suppression of mitophagy under hypoxia conditions. Scale bar: 10 μm. (<b>H</b>,<b>J</b>) Flow cytometry analysis showed that overexpression of TFAM could reverse OA-induced downregulation of MMP level in HepG2 cells. Data are expressed as mean ± SEM, where * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, and *** <span class="html-italic">p</span> &lt; 0.001 denote statistical significance.</p>
Full article ">Figure 5
<p>OA suppressed mitophagy by downregulating TFAM to reduce p53 acetylation under hypoxia conditions. (<b>A</b>) Western blot showed that knocking down TFAM could reduce p53 expression under hypoxia conditions. (<b>B</b>) RT-PCR analysis was used to determine the levels of p53 mRNA in HepG2 cells after TFAM knockdown. (<b>C</b>) Western blot assessed the effects of combining CHX or MG132 with OA on p53 protein. (<b>D</b>) After treatment with CHX in the presence or absence of OA, Western blot analysis evaluated the expression of p53 protein at the indicated time. (<b>E</b>) Co-IP detected the ubiquitination levels of p53 following treatment with either TFAM knockdown or 10 μM OA for 24 h. (<b>F</b>) Western blot investigated the effects of TFAM knockdown on the expression of acetylated p53 protein and its downstream target proteins. (<b>G</b>) After treatment with OA for 24 h, Western blot assessed the impact of OA on acetylated p53 and its downstream target protein. (<b>H</b>) Western blot showed that overexpressing TFAM could reverse the effects of OA on p53 acetylation and its downstream target genes. Data are expressed as mean ± SEM, where * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, and *** <span class="html-italic">p</span> &lt; 0.001 denote statistical significance.</p>
Full article ">Figure 6
<p>OA enhanced the therapeutic effect of sorafenib on xenograft tumor in vivo. (<b>A</b>) Changes in body weight of mice in each group. (<b>B</b>) Quantification of tumor weight in each group. (<b>C</b>) Volume changes of tumors in each group. (<b>D</b>) Immunohistochemical analysis of TFAM expression in tumor tissues of mice in each group. (<b>E</b>) Western blot analysis of the expression of mitophagy-related proteins in tumor tissues. Data are expressed as mean ± SEM, where * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, and *** <span class="html-italic">p</span> &lt; 0.001 denote statistical significance.</p>
Full article ">
Back to TopTop